Evidence map›Paper›PMID 26430882›Full record

ArticlePloS one2015

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.

Marie R McCausland, Steven M Juchnowski, David A Zidar, Daniel R Kuritzkes, Adriana Andrade, Scott F Sieg, Michael M Lederman, Nicholas T Funderburg

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Marie R McCauslandDivision of Infectious Disease, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Steven M JuchnowskiHarrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America.
David A ZidarDivision of Infectious Disease, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America; Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
Adriana AndradeDepartment of Medicine, Division of Infectious Diseases, John Hopkins University, Baltimore, Maryland, United States of America.
Scott F SiegDivision of Infectious Disease, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Michael M LedermanDivision of Infectious Disease, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Nicholas T FunderburgSchool of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, Columbus, Ohio, United States of America.
University Hospitals Case Medical Center · USUniversity School · USCase Western Reserve University · USHarvard University · USThe Ohio State University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Cellular mediators of vascular inflammation in treated HIV infectionR56HL126563 · NHLBI · OHIO STATE UNIVERSITY · PI FUNDERBURG, NICHOLAS T. · 2014 to 2014
$810k
Tissue factor expression in HIV disease - Implications for cardiovascular riskR00HL108743 · NHLBI · OHIO STATE UNIVERSITY · PI FUNDERBURG, NICHOLAS T. · 2014 to 2016
$747k
NHLBI NIH HHS R00 HL108743NHLBI NIH HHS R56 HL126563NIAID NIH HHS AI36219NIAID NIH HHS AI 68636NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068636NIAID NIH HHS U01AI068636NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

backgroundMonocytes are increasingly implicated in the inflammatory consequences of HIV-1 disease, yet their phenotype following antiretroviral therapy (ART) initiation is incompletely defined. Here, we define more completely monocyte phenotype both prior to ART initiation and during 48 weeks of ART.

methodsCryopreserved peripheral blood mononuclear cells (PBMCs) were obtained at baseline (prior to ART initiation) and at weeks 12, 24, and 48 of treatment from 29 patients participating in ACTG clinical trial A5248, an open label study of raltegravir/emtricitibine/tenofovir administration. For comparison, cryopreserved PBMCs were obtained from 15 HIV-1 uninfected donors, each of whom had at least two cardiovascular risk factors. Thawed samples were stained for monocyte subset markers (CD14 and CD16), HLA-DR, CCR2, CX3CR1, CD86, CD83, CD40, CD38, CD36, CD13, and CD163 and examined using flow cytometry.

resultsIn untreated HIV-1 infection there were perturbations in monocyte subset phenotypes, chiefly a higher frequency and density (mean fluorescence intensity-MFI) of HLA-DR (%-p = 0.004, MFI-p = .0005) and CD86 (%-p = 0.012, MFI-p = 0.005) expression and lower frequency of CCR2 (p = 0.0002) expression on all monocytes, lower CCR2 density on inflammatory monocytes (p = 0.045) when compared to the expression and density of these markers in controls' monocytes. We also report lower expression of CX3CR1 (p = 0.014) on patrolling monocytes at baseline, compared to levels seen in controls. After ART, these perturbations tended to improve, with decreasing expression and density of HLA-DR and CD86, increasing CCR2 density on inflammatory monocytes, and increasing expression and density of CX3CR1 on patrolling monocytes.

conclusionsIn HIV-1 infected patients, ART appears to attenuate the high levels of activation (HLA-DR, CD86) and to increase expression of the chemokine receptors CCR2 and CX3CR1 on monocyte populations. Circulating monocyte phenotypes are altered in untreated infection and tend to normalize with ART; the role of these cells in the inflammatory environment of HIV-1 infection warrants further study.

Indexed as

HIV-1AdultAntigens, CDAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCell SeparationCX3C Chemokine Receptor 1Drug CombinationsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationFemaleFlow CytometryHIV InfectionsHIV Integrase InhibitorsHLA-DR AntigensHumansImmunophenotypingAntigens, CDAnti-HIV AgentsCCR2 protein, humanCX3C Chemokine Receptor 1CX3CR1 protein, humanDrug CombinationsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV Integrase InhibitorsHLA-DR AntigensRaltegravir PotassiumReceptors, CCR2Receptors, Chemokine

Identifiers

PMID26430882
PMCPMC4591977
OpenAlexW2175498742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.